Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Hürthle cell carcinoma.

E Yutan¹, O H Clark

¹Mt. Zion/University of California, San Francisco Medical Center, Department of Surgery, 1600 Divisadero St., Room C-342, San Francisco, CA 94143-1674, USA.

Current Treatment Options in Oncology

|June 12, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Invasion of metastatic human follicular thyroid cancer is inhibited via antagonism of protein kinase C.

Cancer letters·2008

Same author

Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.

Surgery·2007

Same author

Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases.

Surgical endoscopy·2007

Same author

Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?

World journal of surgery·2006

Same author

Parathyroid surgery: we still need traditional and selective approaches.

Journal of endocrinological investigation·2005

Same author

Well differentiated thyroid cancer.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2005

Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026

Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026

Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026

Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026

Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026

Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026

See all related articles

Hürthle cell carcinoma (HCC) is an aggressive thyroid cancer. Treatment involves surgery, radioiodine ablation, and thyroid hormone therapy, with surgery also used for recurrent disease.

Area of Science:

Endocrinology
Oncology
Surgical Oncology

Background:

Hürthle cell carcinoma (HCC) presents aggressive tumor characteristics.
Patients with HCC generally experience a poorer prognosis compared to papillary or follicular thyroid carcinomas.

Purpose of the Study:

To outline the recommended management and treatment strategies for Hürthle cell carcinoma.
To discuss the prognosis and surveillance of HCC patients.

Main Methods:

Surgical management including total thyroidectomy and neck dissection when indicated.
Post-operative radioiodine scanning for completeness assessment and remnant ablation.
Thyroid hormone replacement therapy for all patients.
Surgical intervention for recurrent disease or metastasis.

Related Experiment Videos

Main Results:

Fewer than 10% of Hürthle cell carcinomas demonstrate radioiodine uptake.
Surgical treatment for recurrent disease offers good palliation and survival extension.
Pulmonary wedge resection is effective for lung metastases.

Conclusions:

Comprehensive surgical treatment followed by radioiodine ablation is crucial for HCC management.
Thyroid hormone administration is essential due to thyrotropin receptor presence in most HCCs.
Recurrent HCC can be effectively managed with surgical interventions, prolonging life and improving palliation.